Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Kayleigh Marx"'
Autor:
Shilpa Paul, Hagop Kantarjian, Koji Sasaki, Kayleigh Marx, Nitin Jain, J. Michael Savoy, Adam DiPippo, Nadya Jammal, Guillermo Montalban Bravo, Tapan Kadia, Guillermo Garcia‐Manero, Nicholas J. Short, Farhad Ravandi, Elias Jabbour
Publikováno v:
American journal of hematology. 98(1)
Autor:
Caitlin R. Rausch, Kiran Naqvi, Prithviraj Bose, Wei Qiao, Zeev Estrov, Musa Yilmaz, Kayleigh Marx, Xuelin Huang, Carol Bivins, David McCue, Tapan M. Kadia, Lucia Masarova, Naval Daver, Dimitrios P. Kontoyiannis, Naveen Pemmaraju, Hagop M. Kantarjian, Nathan P. Wiederhold, Koichi Takahashi, Farhad Ravandi, Sherry Pierce, Sebastian Wurster, Marina Konopleva, Gautam Borthakur
Publikováno v:
Clin Infect Dis
Background Mold-active primary antifungal prophylaxis (PAP) is routinely recommended in neutropenic patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) undergoing remission-induction chemotherapy (RI
Autor:
Nicholas J. Short, Gautam Borthakur, Tapan M. Kadia, Courtney D. DiNardo, Hagop M. Kantarjian, Lucia Masarova, Naval Daver, Jorge E. Cortes, Kiran Naqvi, Koji Sasaki, Marina Konopleva, Elias Jabbour, Farhad Ravandi, Kayleigh Marx, Abhishek Maiti, Sherry Pierce, Miguel Franquiz
Publikováno v:
Acta Haematologica. 143:567-573
Background: Philadelphia chromosome-positive (Ph+) advanced leukemias, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) in myeloid blast phase (MBP), have poor outcomes. Venetoclax has shown synergism with BCR-ABL1 tyrosine k
Autor:
Tapan M. Kadia, Mahran Shoukier, Courtney D. DiNardo, Elizabeth J. Shpall, Naval Daver, Kayleigh Marx, Sherry Pierce, Naveen Pemmaraju, Michael Andreeff, Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Sangeetha Venugopal, Nicholas J. Short, Guillermo Garcia-Manero, Gautam Borthakur, Uday R. Popat, Farhad Ravandi, Koji Sasaki, Marina Konopleva, Hagop M. Kantarjian
Publikováno v:
CancerReferences. 127(19)
Background Venetoclax (VEN) in combination with a hypomethylating agent (HMA) has become the standard of care for patients aged >75 years and for those not eligible for intensive chemotherapy who have newly diagnosed acute myeloid leukemia (AML). The
Autor:
Kayleigh Marx, Farhad Ravandi, Nadya Jammal, Dimitrios P. Kontoyiannis, Marina Konopleva, Koichi Takahashi, Naveen Pemmaraju, Serena M. Chew, Ghayas C. Issa, J. Michael Savoy, Koji Sasaki, Courtney D. DiNardo, Lianchun Xiao, Caitlin R. Rausch, Abhishek Maiti, Maro Ohanian, Gautam Borthakur, Jing Ning, Nicholas J. Short, Hagop M. Kantarjian, Tapan M. Kadia, Naval Daver, Yesid Alvarado, Adam J. DiPippo
Publikováno v:
Cancer
Background Venetoclax (VEN) combined with the hypomethylating agent (HMA) azacitidine improves survival in patients aged ≥75 years with newly diagnosed acute myeloid leukemia (AML). VEN and HMA treatment can result in prolonged and often profound n
Autor:
Elias Jabbour, Kayleigh Marx, Shilpa Paul, Hagop M. Kantarjian, Alessandra Ferrajoli, Caitlin R. Rausch, Naveen Pemmaraju
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 18:e191-e195
Autor:
Elias Jabbour, Koji Sasaki, Farhad Ravandi, Hagop M. Kantarjian, Fadi Haddad, Ghayas C. Issa, Kayleigh Marx, Nicholas J. Short, Naveen Pemmaraju
Publikováno v:
Blood. 138:2560-2560
Background: Patients with a history of bariatric surgery are often excluded from clinical trials evaluating oral therapies. This is due to concerns that these surgeries alter bioavailability and drug metabolism. Oral tyrosine kinase inhibitors (TKIs)
Autor:
J P Sanchez, German Contreras, Truc T Tran, Shelby Simar, Blake Hanson, Kayleigh Marx, Marcus Zervos, Katherine Reyes, Jose M Munita, Samuel A Shelburne, Cesar A Arias, Samuel L Aitken
Publikováno v:
Open Forum Infectious Diseases
Background E. faecalis (Efc) isolates are usually susceptible to ampicillin (AMP). AMP-based regimens are the standard of care for enterococcal infections, although other antibiotics are often used as definitive treatment. We thus compared outcomes o
Publikováno v:
Expert Opinion on Orphan Drugs. 4:885-892
Introduction: A first-in-class anticancer quinolone derivative with topoisomerase II activity, mechanistically, vosaroxin is similar to the anthracycline class. However, vosaroxin displays advantageous pharmacokinetic properties such as minimal metab
Autor:
Marina Konopleva, Courtney D. DiNardo, Nadya Jammal, Kayleigh Marx, Koji Sasaki, J. Michael Savoy, Abhishek Maiti, Farhad Ravandi, Tapan M. Kadia, Caitlin R. Rausch, Ghayas C. Issa, Naveen Pemmaraju, Serena Chew, Hagop M. Kantarjian, Kiran Naqvi, Gautam Borthakur, Naval Daver, Adam J. DiPippo
Publikováno v:
Blood. 134:2640-2640
Introduction: Venetoclax (VEN) is approved for the treatment of acute myeloid leukemia (AML) in combination with hypomethylating agents (HMAs) or low-dose cytarabine and commonly used for patients (pts) unfit for intensive chemotherapy. Prophylaxis w